Insider Selling: Belite Bio (NASDAQ:BLTE) CFO Sells 6,200 Shares of Stock

Key Points

• CFO Hao-Yuan Chuang sold 6,200 shares of Belite Bio on April 9 at an average price of $181.50, generating $1,125,300 and reducing his stake by 6.2% to 93,800 shares (about $17.0M); the sale was disclosed in an SEC filing.
• Stock context: BLTE traded near $173.18 with a market cap of $6.81B and a 12‑month range of $53.60–$200, and the company reported quarterly EPS of -$0.38, beating estimates.
• Analyst sentiment: The consensus rating is a "Moderate Buy" with an average price target of $202.33, and several firms have issued buy ratings or raised targets (e.g., Cantor Fitzgerald to $266).

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) CFO Hao-Yuan Chuang sold 6,200 shares of Belite Bio stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $181.50, for a total transaction of $1,125,300.00. Following the transaction, the chief financial officer directly owned 93,800 shares of the company's stock, valued at $17,024,700. This represents a 6.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Belite Bio Stock Performance

BLTE traded up $0.42 during midday trading on Monday, hitting $173.18. The company had a trading volume of 179,113 shares, compared to its average volume of 204,926. The company has a market capitalization of $6.81 billion, a PE ratio of -75.30 and a beta of -1.22. Belite Bio, Inc. Sponsored ADR has a twelve month low of $53.60 and a twelve month high of $200.00. The firm's 50-day simple moving average is $172.04 and its 200-day simple moving average is $142.81.

Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.18. As a group, sell-side analysts anticipate that Belite Bio, Inc. Sponsored ADR will post -1.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on BLTE shares. Wall Street Zen upgraded shares of Belite Bio from a "sell" rating to a "hold" rating in a research report on Saturday, April 4th. Needham & Company LLC set a $217.00 price target on shares of Belite Bio in a research report on Tuesday, March 3rd. Cantor Fitzgerald lifted their price target on shares of Belite Bio from $200.00 to $266.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 3rd. Bank of America began coverage on shares of Belite Bio in a research report on Monday, January 26th. They set a "buy" rating and a $195.00 price target for the company. Finally, Benchmark reiterated a "buy" rating on shares of Belite Bio in a research report on Tuesday, March 3rd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Belite Bio has a consensus rating of "Moderate Buy" and an average price target of $202.33.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its holdings in Belite Bio by 28,200.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company's stock valued at $45,000 after purchasing an additional 282 shares during the period. Bank of America Corp DE grew its holdings in Belite Bio by 28.1% during the third quarter. Bank of America Corp DE now owns 1,171 shares of the company's stock valued at $87,000 after purchasing an additional 257 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Belite Bio during the fourth quarter valued at approximately $103,000. Persistent Asset Partners Ltd acquired a new position in Belite Bio during the fourth quarter valued at approximately $108,000. Finally, GAMMA Investing LLC grew its holdings in Belite Bio by 11.1% during the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company's stock valued at $130,000 after purchasing an additional 176 shares during the period. Institutional investors and hedge funds own 0.53% of the company's stock.

Belite Bio Company Profile

Belite Bio, Inc NASDAQ: BLTE is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.